Close Menu

NEW YORK – Agena Bioscience is preparing to commercially launch a pre-analytical quality control assay that it expects to increase the efficiency of liquid biopsy testing.

In a corporate workshop presentation at the 2020 virtual Association for Molecular Pathology annual meeting this week, an early-access user provided a sneak peek of validation data for the assay, called Liquid IQ, and how it might be used in combination with the company's UltraSeek circulating tumor DNA (ctDNA)-based lung cancer mutation panel.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The UK has given emergency authorization for Pfizer and BioNTech's SARS-CoV-2 vaccine, the Associated Press reports.

A US advisory committee says healthcare workers and nursing home residents should be prioritized to receive a SARS-CoV-2 vaccine, according to the Financial Times.

The Wall Street Journal reports North Korean hackers have targeted half a dozen companies developing SARS-CoV-2 vaccines.

In Cell this week: long-term SARS-CoV-2 shedding, examination of the effects of a coronavirus spike protein mutation, and more.